New insights into the biology of filarial infections.
Identifieur interne : 006142 ( Main/Exploration ); précédent : 006141; suivant : 006143New insights into the biology of filarial infections.
Auteurs : S. Specht [Allemagne] ; S. WanjiSource :
- Journal of helminthology [ 1475-2697 ] ; 2009.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Filariose lymphatique, Onchocercose.
- usage thérapeutique : Antibactériens, Filaricides.
- Animaux, Filariose lymphatique, Humains, Onchocercose.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Filaricides.
- drug therapy : Elephantiasis, Filarial, Onchocerciasis.
- prevention & control : Elephantiasis, Filarial, Onchocerciasis.
- Animals, Humans.
Abstract
Recent successes in the control of lymphatic filariasis and onchocerciasis need continuing research in order to sustain the achievements and to develop further tools to tackle the new questions that arise when only reduced infection prevalences prevail. In this regard, in a symposium held at the Xth European Multicolloquium of Parasitology (August 2008, Paris) questions such as the impact of filarial immunosuppression, and its lack following filarial control, on the outcome of co-infections were addressed, as were new approaches to treatment with promising drugs such as moxidectin or the antibiotic chemotherapy against Wolbachia endosymbionts in filariae. In particular, longer treatment courses of doxycycline could be carried out by community-directed treatment at high coverage, thus potentially allowing its use in restricted areas with suboptimal responses to ivermectin against onchocerciasis, or in areas with co-infection by loiasis where onchocerciasis or lymphatic filariasis need to be controlled. New, more potent drugs, or eventually vaccines, will be of importance because in many vector-filarial parasite relationships worldwide, transmission efficacy increases with low numbers of ingested microfilariae, and since ivermectin may render treated hosts more susceptible to new infection.
DOI: 10.1017/S0022149X09344922
PubMed: 19379544
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002E99
- to stream PubMed, to step Curation: 002E99
- to stream PubMed, to step Checkpoint: 002E99
- to stream Ncbi, to step Merge: 003359
- to stream Ncbi, to step Curation: 003359
- to stream Ncbi, to step Checkpoint: 003359
- to stream Main, to step Merge: 006215
- to stream Main, to step Curation: 006142
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New insights into the biology of filarial infections.</title><author><name sortKey="Specht, S" sort="Specht, S" uniqKey="Specht S" first="S" last="Specht">S. Specht</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany. specht@parasit.meb.uni-bonn.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Bonn</settlement></placeName></affiliation></author><author><name sortKey="Wanji, S" sort="Wanji, S" uniqKey="Wanji S" first="S" last="Wanji">S. Wanji</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19379544</idno><idno type="pmid">19379544</idno><idno type="doi">10.1017/S0022149X09344922</idno><idno type="wicri:Area/PubMed/Corpus">002E99</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E99</idno><idno type="wicri:Area/PubMed/Curation">002E99</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E99</idno><idno type="wicri:Area/PubMed/Checkpoint">002E99</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002E99</idno><idno type="wicri:Area/Ncbi/Merge">003359</idno><idno type="wicri:Area/Ncbi/Curation">003359</idno><idno type="wicri:Area/Ncbi/Checkpoint">003359</idno><idno type="wicri:Area/Main/Merge">006215</idno><idno type="wicri:Area/Main/Curation">006142</idno><idno type="wicri:Area/Main/Exploration">006142</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">New insights into the biology of filarial infections.</title><author><name sortKey="Specht, S" sort="Specht, S" uniqKey="Specht S" first="S" last="Specht">S. Specht</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany. specht@parasit.meb.uni-bonn.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Bonn</settlement></placeName></affiliation></author><author><name sortKey="Wanji, S" sort="Wanji, S" uniqKey="Wanji S" first="S" last="Wanji">S. Wanji</name></author></analytic><series><title level="j">Journal of helminthology</title><idno type="eISSN">1475-2697</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>Onchocerciasis (drug therapy)</term><term>Onchocerciasis (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antibactériens (usage thérapeutique)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Onchocercose ()</term><term>Onchocercose (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Onchocercose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Filaricides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Filariose lymphatique</term><term>Humains</term><term>Onchocercose</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent successes in the control of lymphatic filariasis and onchocerciasis need continuing research in order to sustain the achievements and to develop further tools to tackle the new questions that arise when only reduced infection prevalences prevail. In this regard, in a symposium held at the Xth European Multicolloquium of Parasitology (August 2008, Paris) questions such as the impact of filarial immunosuppression, and its lack following filarial control, on the outcome of co-infections were addressed, as were new approaches to treatment with promising drugs such as moxidectin or the antibiotic chemotherapy against Wolbachia endosymbionts in filariae. In particular, longer treatment courses of doxycycline could be carried out by community-directed treatment at high coverage, thus potentially allowing its use in restricted areas with suboptimal responses to ivermectin against onchocerciasis, or in areas with co-infection by loiasis where onchocerciasis or lymphatic filariasis need to be controlled. New, more potent drugs, or eventually vaccines, will be of importance because in many vector-filarial parasite relationships worldwide, transmission efficacy increases with low numbers of ingested microfilariae, and since ivermectin may render treated hosts more susceptible to new infection.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>District de Cologne</li><li>Rhénanie-du-Nord-Westphalie</li></region><settlement><li>Bonn</li></settlement></list><tree><noCountry><name sortKey="Wanji, S" sort="Wanji, S" uniqKey="Wanji S" first="S" last="Wanji">S. Wanji</name></noCountry><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Specht, S" sort="Specht, S" uniqKey="Specht S" first="S" last="Specht">S. Specht</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006142 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006142 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19379544
|texte= New insights into the biology of filarial infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19379544" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |